一般外科

1.Yang PM, Hong YH, Hsu KC, Liu TP; p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma. American journal of cancer research. 2019 Oct 1; 9(10):2120-2139 2.Yang PM, Lin LS, Liu TP; Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Biomolecules 2020 Jan 9; 10(1). pii: E117 3.Hsieh YY, Liu TP, Chou CJ, Chen HY, Lee KH, Yang PM; Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma. Genes. 2019 Sep 28; 10(10) 4.Cheng CS, Liu TP, Chien FC, Mou CY, Wu SH, Chen YP; Codelivery of Plasmid and Curcumin with Mesoporous Silica Nanoparticles for Promoting Neurite Outgrowth. ACS applied materials & interfaces. 2019 May 1; 11(17):15322-15331 5.Hsieh YY, Liu TP, Yang PM; In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing clear cell renal carcinoma. Pathology, research and practice. 2019;215(6):152373 6.Tsai CH, Yang PS, Lee JJ, Liu TP, Kuo CY, Cheng SP; Effects of Preoperative Iodine Administration on Thyroidectomy for Hyperthyroidism: A Systematic Review and Meta-analysis. Otolaryngology--head and neck surgery. 2019 Jun; 160(6):993-1002 7.Liu TP, Hsieh YY, Chou CJ, Yang PM; Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining. Royal Society open science. 2018 Nov 28; 5(11):181321 8.Chien MN, Yang PS, Hsu YC, Liu TP, Lee JJ, Cheng SP; Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation. Head & neck. 2018 Nov; 40(11):2528-2537